Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Senior Vice President | April 21, 2020 | April 24, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date April 21, 2020 · Filed April 24, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 62,205 |
Ending reported balance
After 2020-04-21 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2020-04-21 · Exercise / conversion · Acquired 46,016 · Balance 83,035 Row 2 · 2020-04-21 · Exercise / conversion · Acquired 36,715 · Balance 119,750 Row 3 · 2020-04-21 · Exercise / conversion · Acquired 25,681 · Balance 145,431 Row 4 · 2020-04-21 · Tax withholding · Disposed 83,226 · Balance 62,205 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.40 · Expires 2027-02-16 | Direct | 0 |
Reported balance
After 2020-04-21 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-04-21 · Exercise / conversion · Disposed 46,016 · Balance 0 F5: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.94 · Expires 2028-02-15 | Direct | 36,715 |
Reported balance
After 2020-04-21 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-04-21 · Exercise / conversion · Disposed 36,715 · Balance 36,715 F6: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.90 · Expires 2029-02-21 | Direct | 51,364 |
Reported balance
After 2020-04-21 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-04-21 · Exercise / conversion · Disposed 25,681 · Balance 51,364 F6: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 22 |
Reported balance
Holding disclosure · report date 2020-04-21 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 22 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of April 21, 2020. |
| Common shares without par valueSEC Table I · non-derivative | IndirectJaime Contreras Marvan 2006 Living Trust | 176,217 |
Reported balance
Holding disclosure · report date 2020-04-21 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 176,217 F2: Held in the Jaime Contreras Marvan 2006 Living Trust. The reporting person is sole trustee of the trust. The trust is revocable. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy Spouse | 2,624 |
Reported balance
Holding disclosure · report date 2020-04-21 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 2,624 F3: The reporting person disclaims beneficial ownership of all securities held by his spouse. |
| Common shares without par valueSEC Table I · non-derivative | IndirectLiving Trust (by spouse) | 12,081 |
Reported balance
Holding disclosure · report date 2020-04-21 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 12,081 F4: Held in spouse's living trust. The reporting person's spouse is sole trustee of the trust. The trust is revocable. The reporting person disclaims beneficial ownership of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of April 21, 2020.
F2: Held in the Jaime Contreras Marvan 2006 Living Trust. The reporting person is sole trustee of the trust. The trust is revocable.
F3: The reporting person disclaims beneficial ownership of all securities held by his spouse.
F4: Held in spouse's living trust. The reporting person's spouse is sole trustee of the trust. The trust is revocable. The reporting person disclaims beneficial ownership of these securities.
F5: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
F6: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2015 Filed Mar 3, 2015 22:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 9,209 | $47.34 | $435,954.06 |
DisclosureSEC source: 0001179110-15-004049 · edgar.xml · nonDerivative · entry 2 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,898 Read SEC document |
| February 27, 2015 Filed Mar 3, 2015 22:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,826 | $47.61 | $229,765.86 |
DisclosureSEC source: 0001179110-15-004049 · edgar.xml · nonDerivative · entry 1 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,107 Read SEC document |
| February 20, 2015 Filed Feb 24, 2015 23:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 146,551 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003368 · edgar.xml · derivative · entry 6 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,551 Underlying: Common shares · 146,551 shares Expires 2025-02-19 F6 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 48,851 on 2/20/16, 48,850 on 2/20/17, and 48,850 on 2/20/18. Read SEC document |
| February 20, 2015 Filed Feb 24, 2015 23:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 20,797 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003368 · edgar.xml · nonDerivative · entry 1 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,933 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 18, 2015 Filed Feb 18, 2015 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 423 | $46.26 | $19,567.98 |
DisclosureSEC source: 0001179110-15-002826 · edgar.xml · nonDerivative · entry 6 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,379 Read SEC document |
| February 17, 2015 Filed Feb 18, 2015 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 98 | $46.09 | $4,516.82 |
DisclosureSEC source: 0001179110-15-002826 · edgar.xml · nonDerivative · entry 5 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,802 Read SEC document |
| February 15, 2015 Filed Feb 18, 2015 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 146 | $46.09 | $6,729.14 |
DisclosureSEC source: 0001179110-15-002826 · edgar.xml · nonDerivative · entry 4 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,900 Read SEC document |
| November 25, 2014 Filed Nov 26, 2014 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 17,700 | $0.00 Strike: $26.02 | $0.00 |
DisclosureSEC source: 0001179110-14-017222 · edgar.xml · derivative · entry 17 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 17,700 shares Expires 2019-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 25, 2014 Filed Nov 26, 2014 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 33,900 | $0.00 Strike: $26.70 | $0.00 |
DisclosureSEC source: 0001179110-14-017222 · edgar.xml · derivative · entry 16 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 33,900 shares Expires 2018-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 25, 2014 Filed Nov 26, 2014 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,400 | $44.09 | $61,727.40 |
DisclosureSEC source: 0001179110-14-017222 · edgar.xml · nonDerivative · entry 11 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,136 Read SEC document |
| November 25, 2014 Filed Nov 26, 2014 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 255 | $44.09 | $11,242.95 |
DisclosureSEC source: 0001179110-14-017222 · edgar.xml · nonDerivative · entry 10 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,536 Read SEC document |
| November 25, 2014 Filed Nov 26, 2014 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,064 | $44.08 | $46,901.12 |
DisclosureSEC source: 0001179110-14-017222 · edgar.xml · nonDerivative · entry 9 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,791 Read SEC document |
| November 25, 2014 Filed Nov 26, 2014 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $44.07 | $13,221.90 |
DisclosureSEC source: 0001179110-14-017222 · edgar.xml · nonDerivative · entry 8 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,855 Read SEC document |
| November 25, 2014 Filed Nov 26, 2014 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $44.07 | $8,814.40 |
DisclosureSEC source: 0001179110-14-017222 · edgar.xml · nonDerivative · entry 7 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,155 Read SEC document |
| November 25, 2014 Filed Nov 26, 2014 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 35,607 | $44.07 | $1,569,236.10 |
DisclosureSEC source: 0001179110-14-017222 · edgar.xml · nonDerivative · entry 6 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,355 Read SEC document |
| November 25, 2014 Filed Nov 26, 2014 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 11,374 | $44.07 | $501,252.18 |
DisclosureSEC source: 0001179110-14-017222 · edgar.xml · nonDerivative · entry 5 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,962 Read SEC document |
| November 25, 2014 Filed Nov 26, 2014 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $44.06 | $13,218.30 |
DisclosureSEC source: 0001179110-14-017222 · edgar.xml · nonDerivative · entry 4 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,336 Read SEC document |
| November 25, 2014 Filed Nov 26, 2014 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,100 | $44.06 | $48,466.00 |
DisclosureSEC source: 0001179110-14-017222 · edgar.xml · nonDerivative · entry 3 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,636 Read SEC document |
| November 25, 2014 Filed Nov 26, 2014 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 17,700 | $26.02 | $460,465.50 |
DisclosureSEC source: 0001179110-14-017222 · edgar.xml · nonDerivative · entry 2 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,736 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2014 Filed Nov 26, 2014 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 33,900 | $26.70 | $905,038.47 |
DisclosureSEC source: 0001179110-14-017222 · edgar.xml · nonDerivative · entry 1 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2014 Filed Nov 12, 2014 23:54 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 3,200 | $0.00 Strike: $26.70 | $0.00 |
DisclosureSEC source: 0001179110-14-016462 · edgar.xml · derivative · entry 13 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 Underlying: Common shares · 3,200 shares Expires 2018-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 10, 2014 Filed Nov 12, 2014 23:54 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 3,100 | $0.00 Strike: $25.76 | $0.00 |
DisclosureSEC source: 0001179110-14-016462 · edgar.xml · derivative · entry 12 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 Underlying: Common shares · 3,100 shares Expires 2017-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 10, 2014 Filed Nov 12, 2014 23:54 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,100 | $43.69 | $48,055.70 |
DisclosureSEC source: 0001179110-14-016462 · edgar.xml · nonDerivative · entry 10 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 2,046 Read SEC document |
| November 10, 2014 Filed Nov 12, 2014 23:54 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $43.69 | $17,474.00 |
DisclosureSEC source: 0001179110-14-016462 · edgar.xml · nonDerivative · entry 9 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 3,146 Read SEC document |
| November 10, 2014 Filed Nov 12, 2014 23:54 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $43.68 | $26,209.80 |
DisclosureSEC source: 0001179110-14-016462 · edgar.xml · nonDerivative · entry 8 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 3,546 Read SEC document |
| November 10, 2014 Filed Nov 12, 2014 23:54 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,200 | $43.68 | $183,460.20 |
DisclosureSEC source: 0001179110-14-016462 · edgar.xml · nonDerivative · entry 7 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 4,146 Read SEC document |
| November 10, 2014 Filed Nov 12, 2014 23:54 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 3,200 | $26.70 | $85,431.36 |
DisclosureSEC source: 0001179110-14-016462 · edgar.xml · nonDerivative · entry 6 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 8,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2014 Filed Nov 12, 2014 23:54 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 3,100 | $25.76 | $79,842.05 |
DisclosureSEC source: 0001179110-14-016462 · edgar.xml · nonDerivative · entry 5 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 5,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2014 Filed Nov 12, 2014 23:54 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | OtherCommon shares without par value | 16 | $41.75 | $668.05 |
DisclosureSEC source: 0001179110-14-016462 · edgar.xml · nonDerivative · entry 3 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · Profit Sharing Trust (by spouse) Disclosed balance after: 0 F1 · balance_after: Balance in the Abbott Laboratories Stock Retirement Trust as of November 10, 2014. Read SEC document |
| March 31, 2014 Filed Apr 2, 2014 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 979 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-006275 · edgar.xml · nonDerivative · entry 5 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 2,046 F3 · shares: This grant represents a restricted stock unit award under the Abbott Laboratories 2009 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting on each anniverary of the grant date. The award includes the right to have stock withheld for tax purposes. Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $39.38 | $23,630.40 |
DisclosureSEC source: 0001179110-14-004301 · edgar.xml · nonDerivative · entry 5 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,136 Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,000 | $39.38 | $78,762.00 |
DisclosureSEC source: 0001179110-14-004301 · edgar.xml · nonDerivative · entry 4 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,736 Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 650 | $39.37 | $25,590.50 |
DisclosureSEC source: 0001179110-14-004301 · edgar.xml · nonDerivative · entry 3 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,736 Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,831 | $39.37 | $190,177.15 |
DisclosureSEC source: 0001179110-14-004301 · edgar.xml · nonDerivative · entry 2 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,386 Read SEC document |
| February 28, 2014 Filed Mar 4, 2014 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 3,919 | $39.79 | $155,937.01 |
DisclosureSEC source: 0001179110-14-004301 · edgar.xml · nonDerivative · entry 1 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,217 Read SEC document |
| February 21, 2014 Filed Feb 25, 2014 22:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption(right to buy) · Derivative | 112,668 | $0.00 Strike: $39.12 | $0.00 |
DisclosureSEC source: 0001179110-14-003623 · edgar.xml · derivative · entry 7 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,668 Underlying: Common shares · 112,668 shares Expires 2024-02-20 F6 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 37,556 on 2/21/2015, 37,556 on 2/21/2016, and 37,556 on 2/21/2017. Read SEC document |
| February 21, 2014 Filed Feb 25, 2014 22:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 18,403 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-003623 · edgar.xml · nonDerivative · entry 1 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,136 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 18, 2014 Filed Feb 19, 2014 23:53 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 621 | $38.96 | $24,191.06 |
DisclosureSEC source: 0001179110-14-003110 · edgar.xml · nonDerivative · entry 7 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,067 F3 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his spouse. Read SEC document |
| February 18, 2014 Filed Feb 19, 2014 23:53 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 126 | $38.81 | $4,890.06 |
DisclosureSEC source: 0001179110-14-003110 · edgar.xml · nonDerivative · entry 6 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,688 F3 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his spouse. Read SEC document |
| February 17, 2014 Filed Feb 19, 2014 23:53 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 101 | $38.81 | $3,919.81 |
DisclosureSEC source: 0001179110-14-003110 · edgar.xml · nonDerivative · entry 5 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,814 Read SEC document |
| February 15, 2014 Filed Feb 19, 2014 23:53 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 151 | $38.81 | $5,860.31 |
DisclosureSEC source: 0001179110-14-003110 · edgar.xml · nonDerivative · entry 4 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,915 F3 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his spouse. Read SEC document |
| October 30, 2013 Filed Nov 1, 2013 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 2,715 | $0.00 Strike: $35.08 | $0.00 |
DisclosureSEC source: 0001179110-13-015959 · edgar.xml · derivative · entry 12 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 0 Underlying: Common shares · 2,715 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: The reporting person disclaims beneficial ownership of all securities held by his spouse. F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| October 30, 2013 Filed Nov 1, 2013 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 1,545 | $0.00 Strike: $35.08 | $0.00 |
DisclosureSEC source: 0001179110-13-015959 · edgar.xml · derivative · entry 11 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 1,545 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| October 30, 2013 Filed Nov 1, 2013 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 21,108 | $0.00 Strike: $33.37 | $0.00 |
DisclosureSEC source: 0001179110-13-015959 · edgar.xml · derivative · entry 10 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 21,108 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| October 30, 2013 Filed Nov 1, 2013 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,715 | $37.01 | $100,484.87 |
DisclosureSEC source: 0001179110-13-015959 · edgar.xml · nonDerivative · entry 7 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 2,066 F3 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his spouse. Read SEC document |
| October 30, 2013 Filed Nov 1, 2013 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 2,715 | $35.08 | $95,242.20 |
DisclosureSEC source: 0001179110-13-015959 · edgar.xml · nonDerivative · entry 6 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 4,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his spouse. Read SEC document |
| October 30, 2013 Filed Nov 1, 2013 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 22,653 | $36.83 | $834,230.70 |
DisclosureSEC source: 0001179110-13-015959 · edgar.xml · nonDerivative · entry 3 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,733 Read SEC document |
| October 30, 2013 Filed Nov 1, 2013 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 1,545 | $35.08 | $54,198.60 |
DisclosureSEC source: 0001179110-13-015959 · edgar.xml · nonDerivative · entry 2 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2013 Filed Nov 1, 2013 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 21,108 | $33.37 | $704,373.96 |
DisclosureSEC source: 0001179110-13-015959 · edgar.xml · nonDerivative · entry 1 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.